Screener
Lucid Diagnostics LUCD Q3 2026 earnings
Reported November 12, 2026 · Before market open
Revenue$1.2MMiss by $428.1K
EPS-$0.06Miss by $0.00
Revenue estimate$1.6M
EPS estimate-$0.06
“This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”
Next report
Date not yet announcedValuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Lucid Diagnostics report Q3 2026 earnings?
- Lucid Diagnostics (LUCD) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Lucid Diagnostics's Q3 2026 revenue and EPS?
- Lucid Diagnostics reported revenue of $1.2M and eps of $-0.06 for Q3 2026.
- Did Lucid Diagnostics beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $1.6M by $428.1K. EPS missed the consensus estimate of $-0.06 by $0.00.
- How did Lucid Diagnostics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 0.7% from $1.2M a year earlier and eps grew 40.0% from $-0.10.
- Where can I find Lucid Diagnostics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001493152-26-051207) and the 10-Q periodic report (0001437749-26-036390) directly on SEC EDGAR. The filing index links above go to sec.gov.
